Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus
Status:
Withdrawn
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Post-transplant diabetes mellitus (PTDM) develops in up to 30% of patients undergoing solid
organ transplantation. This disease is difficult to treat as the levels of glycemia fluctuate
in response to variations in doses of steroid and other immunosuppressive agents. At the same
time, poorly controlled hyperglycemia affects negatively graft function and survival as well
as on the ability of the immunocompromised host to fight infections. The investigators
hypothesize that the addition of Pramlintide (Symlin) to the management of patients with PTDM
would help patients with post-transplant diabetes attain better control at the critical time
of titration of immunosuppressive regimens. The primary objective of this proposal is to
improve glycemic control of diabetes with Pramlintide in patients with post-transplant
diabetes at 3 and 6 months of therapy.